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populationYouth, which is forgiven everything, forgives itself
nothing: age, which forgives itself everything, is forgiven
nothing.
e George Bernard Shaw
The proportion of older people in the general population is
steadily increasing worldwide, with the most rapid growth
in low- and middle-income countries.1 This demographic
change is to be celebrated, because it is the consequence
of socioeconomic development and better life expectancy.
However, population aging also has important implications
for societydin diverse areas including health systems,
labor markets, public policy, social programs, and family
dynamics.2 A successful response to the aging population
will require capitalizing on the opportunities that this
transition offers, as well as effectively addressing its
challenges.
Chronic kidney disease (CKD) is an important public
health problem that is characterized by poor health out-
comes and very high health care costs. CKD is a major risk
multiplier in patients with diabetes, hypertension, heart
disease, and strokedall of which are key causes of death
and disability in older people.3 Because the prevalence of
CKD is higher in older people, the health impact of popu-
lation aging will depend in part on how the kidney com-
munity responds.
March 13, 2014 will mark the celebration of the 9th
World Kidney Day (WKD), an annual event jointly spon-
sored by the International Society of Nephrology and the
International Federation of Kidney Foundations. Since its
inception in 2006, WKD has become the most successful
effort to raise awareness among policymakers and
the general public about the importance of kidney dis-
ease. The topic for WKD 2014 is “CKD in Older People”.
This article reviews the key links between kidney func-
tion, age, health, and illnessdand discusses the impli-
cations of the aging population for the care of people
with CKD.http://dx.doi.org/10.1016/j.hkjn.2014.02.004
1561-5413/Copyright ª 2014, Hong Kong Society of Nephrology Ltd. PuEpidemiology of aging
The key drivers of population aging are: socioeconomic
development and increasing prosperitydwhich result in
lower perinatal, infant, and childhood mortality; lower risk
of death in early adulthood due to accidents and unsafe
living conditions; and improving survival of middle-aged and
older people with chronic disease. The resulting increases
in life expectancy (together with the lower birth rates that
typically accompany socioeconomic development) mean
that older people account for a larger proportion of the
general population.1 The extent of the resulting changes in
population characteristics can be startling, especially for
developing countries (Fig. 1).
In contrast to the situation even two generations ago,
people can expect to live for many years after the usual
retirement age. For example, in the UK, men and women
aged 65 years in 2030 can expect to live until age 88 years
and 91 years, respectively.4 Predicted life expectancy for
today’s children is controversial, but experts estimate that
50% of UK children born in 2007 will live to at least 103
years.4 Although it is clear that people are living longer, it is
uncertain how much of the increased life expectancy will
translate into years of good health. These demographic
changes have dramatic potential implications for conditions
such as CKD, for which the prevalence increases with age.
CKD is common in older people and its preva-
lence increases in parallel with age
It has been known for decades that estimated glomerular
filtration rate (eGFR) declines in parallel with age.5 The
prevalence of CKD among females in the Chinese general
population increases from 7.4% among those aged 18e39
years to 18.0% and 24.2% among those aged 60e69 years
and 70 years, respectively.6 Relative increases in the
prevalence of CKD with age are equally striking for pop-
ulations in the USA, Canada, and Europe,7e9 although thereblished by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Changing age distribution in the general population of China, 1990e2050. Reproduced from WHO document number
WHO/DCO/WHD/2012.2.
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prevalence.
At older ages, an increased proportion of prevalent CKD
cases have low eGFR alone (as compared to albuminuria
alone, or both low eGFR and albuminuria).10 Although this
might suggest that many older people with CKD can expect
lower rates of kidney function loss, available data are
inconclusivedand current knowledge does not allow clini-
cians to distinguish reliably between those whose CKD will
and will not progress.
As for other age groups, the incidence of dialysis-
dependent kidney failure has steadily increased among
older people over the past few decades: in the USA, a 57%
age-adjusted increase in the number of incident octoge-
narians andnonagenarianswas notedbetween 1996 and 2003
alone.11 Despite this increase, patients aged > 80 years are
still less likely to initiate dialysis than those aged 75e79
yearsdalthough a large recent study suggested that the risk
of developing very low eGFR (< 15 mL/minute/1.73 m2) is
similar for older and younger adults.12 It is uncertainwhether
this discrepancy is due to between-age differences in the
true rate of progressive kidney function loss, the risk of death
due to competing causes, patient views about dialysis, or
physician practices.12,13 Regardless of the explanation, theaging population is likely to lead to continued increases in
the number of older people with severe CKD.
CKD is harmful but treatable if patients at risk
are identified
Like younger people, older people with advanced CKD are at
increased risk of death, kidney failure, myocardial infarc-
tion, and stroke compared to otherwise similar people with
normal or mildly reduced eGFR.14,15 Although death is by far
the most common of these adverse outcomes, this does not
mean that older patients with clinically relevant CKD cannot
benefit from timely specialist referral.
With appropriate management, patients with advanced
CKD (regardless of age) may benefit from slower loss of
kidney function (potentially preventing kidney failure),
better control of metabolic consequences such as acidosis,
anemia, and hyperphosphatemia, lower risk of cardiovas-
cular events, and (for those who are interested in renal
replacement) a more informed choice of renal replacement
modality, including timely creation of vascular access.16
The aging population is likely to lead to continued in-
creases in the number of older people who might require
Box 1. Unmet needs for kidney transplantation in older
CKD patients.
 Organ shortage
 Paucity of live donors
 Organ allocation policies that appropriately weight
likelihood of benefit from transplantation as well as
chronological age
 Ensuring appropriate referral of potentially suitable
older recipients for transplantation assessment
 Ethical concerns about offering a kidney to an older
patient versus a younger one
 Optimal immunosuppressive regimen
Note. From “Kidney transplantation in the elderly: it’s
not all gloom and doom,” by V. Mohanlal and M. Weir,
2011, ASN Kidney News, 3, p.15e7. Copyright 2011,
American Society of Nephrology. Adapted with
permission.
Box 2. Meeting the growing demand for kidney trans-
plantation in older CKD patients.
 Preferential transplantation of organs from older
donors to older recipients
 Enlarge the donor pool by accepting expanded
criteria donors: age  60 years or  50 years with
any two of the following conditions: history of hy-
pertension, serum creatinine  1.5 mg/dL or death
due to cerebrovascular accident.
 Transplanting two marginal kidneys instead of one
Note. From “Kidney transplantation in the elderly: it’s
not all gloom and doom,” by V. Mohanlal and M. Weir,
2011, ASN Kidney News, 3, p.15e7. Copyright 2011,
American Society of Nephrology. Adapted with
permission.
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future nephrology workforce capacity.
Dialysis can benefit older people with kidney
failure
In developed countries, the default management strategy
for older people with kidney failure appears to have shifted
from conservative management to initiation of dialysis.17 On
average, life expectancy after initiation of dialysis is rela-
tively short for older patients: median survival among inci-
dent US dialysis patients aged 80e84 years is 16monthsdand
is only 12 months among those aged 85e89 years.11 At the
same time, these median statistics reflect a bimodal distri-
bution of survival time in older dialysis patients: although a
large proportion die within 6months of commencing dialysis,
a substantial minority may live for years. This heterogeneity
in mortality appears to be driven by differences in baseline
comorbidity. For example, analyses of a small UK cohort of
people with advanced kidney failure suggested that initia-
tion of dialysis was not associated with increased survival for
those aged > 75 years and with two or more comorbid-
ities.18,19 Similarly, the presence of two or three comorbid
conditions in US dialysis patients aged > 65 years was asso-
ciated with substantially increased mortality compared to
those in better health.11 When functional status is lower at
baseline, initiation of dialysis often signals the onset of
further declines: among 3702 nursing home residents initi-
ating dialysis, 58% had died and 87% had experienced addi-
tional loss of function at 1 year.20 Although available data
have limitations, quality of life appears reasonable among
selected older dialysis patientsdand can remain stable
despite moderate or high levels of comorbidity.21,22
These data suggest that dialysis is an appropriate
treatment option for well-informed older patients with
kidney failuredespecially for those with a good baseline
quality of life. However, the very poor outcomes experi-
enced in those with more comorbidity or lower functional
status at baseline clearly demonstrate that dialysis does not
improve clinical outcomes for all older people with kidney
failuredand that good clinical judgment and careful
communication will be increasingly required as the general
population continues to age.
Kidney transplantation can also benefit older
people with kidney failure
It is generally accepted that older age alone does not
preclude kidney transplantation in otherwise suitable can-
didates. However, older patients with kidney failure are
more likely to have absolute and relative contraindications
to transplantation, and are less likely to be placed on the
kidney transplantation waiting list. Unsurprisingly, patient
and graft 5-year survival probabilities are lower among US
kidney transplant recipients aged  65 years as compared
to those aged 35e49 years (patient: 67.2% vs. 89.6%; graft:
60.9% vs. 75.4%, respectively).23 In addition, older people
who are potential kidney transplant recipients face several
potential disadvantages compared to their younger coun-
terparts (Box 1).Nonetheless, transplantation appears to reduce mortal-
ity among patients of all ages. For example, among those
aged 74 years, receiving a deceased donor transplant was
associated with a hazard ratio of mortality of 0.67 (95%
confidence interval, 0.53e0.86) as compared to remaining
on dialysis.23 Use of expanded criteria deceased donors24,25
as well as more liberal use of older living donors26 also
appear to reduce mortality among older people with kidney
failure, as compared to similar patients who remain on the
transplant waiting list (Box 2). These latter two strategies
are especially appealing for use in developing countries,
where growth in the prevalence of older people has been
most pronounced. However, because transplant surgery it-
self temporarily increases the risk of death, the mortality
benefits associated with kidney transplantation (regardless
of donor type) are restricted to those with reasonable
baseline life expectancy and without dramatically
increased perioperative risk.27
Editorial 5Research needs
Although much is known about CKD in older populations, a
great deal remains to be learned. Many trials of therapies
for CKD have excluded older patients28dand most do not
provide guidance on how to manage comorbidities that
often accompany CKD but may lead to competing thera-
peutic priorities. More information is needed on how to
accurately identify people who will progress to kidney
failuredand among these, the subset that can expect
reasonable life expectancy and quality of life if they opt for
dialysis treatment. Future studies should test new ways to
communicate information about the risks and benefits of
dialysis (as compared to conservative management), to
facilitate informed patient decisions. Above all, we need
more studies that demonstrate how to optimize quality of
life and manage symptoms in elderly people with
CKDdincluding those who have chosen conservative
management.
The way forward
The aging of the general population means that older
people now account for a much greater proportion of pa-
tients with or at risk for kidney disease and kidney failure.
The tremendous clinical heterogeneity within this popula-
tion indicates the need for more discerning management.
Chronological age alone will not be sufficient as the basis
for clinical decisions, and a more nuanced approach is
requireddbased on the comorbidities, functional status,
quality of life, and preferences of each individual patient.
Clinicians can be reassured that dialysis and kidney trans-
plantation can increase life expectancydand will allow
reasonable quality of life in selected older people with
kidney failure. Perhaps more importantly, clinicians, pa-
tients, and their families can be comforted by the knowl-
edge that timely specialist evaluation can help to improve
outcomes and reduce symptoms in older people with
advanced kidney diseasedwhether they have selected
conservative management or dialysis as their treatment
plan.
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